Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer

Ann Intern Med. 1977 Sep;87(3):293-8. doi: 10.7326/0003-4819-87-3-293.

Abstract

Fifty patients with disseminated testicular cancer were treated with a three-drug combination consisting of cis-diamminedichloroplatinum, vinblastine, and bleomycin. Three patients were considered inevaluable due to early death. This chemotherapy regimen produced 74% complete and 26% partial remissions. Furthermore, five patients with partial remission became disease-free after surgical removal of residual disease, producing an overall 85% disease-free status. Toxicity, although significant during remission induction with cis-platinum, vinblastine, and bleomycin, was usually manageable, although there were two drug-related deaths during this period. Thirty-eight of these patients remain alive and 32 remain alive and disease-free at 6 + to 30 + months. We believe this regimen represents a major advance in the management of patients with disseminated testicular cancer.

MeSH terms

  • Adolescent
  • Adult
  • Bleomycin / adverse effects
  • Bleomycin / therapeutic use*
  • Cisplatin / adverse effects
  • Cisplatin / therapeutic use*
  • Drug Therapy, Combination
  • Humans
  • Leukopenia / chemically induced
  • Male
  • Middle Aged
  • Remission, Spontaneous
  • Testicular Neoplasms / drug therapy*
  • Uremia / chemically induced
  • Vinblastine / adverse effects
  • Vinblastine / therapeutic use*

Substances

  • Bleomycin
  • Vinblastine
  • Cisplatin